The expanding diagnostic toolbox for rare genetic diseases.
Kristin D KernohanKym M BoycottPublished in: Nature reviews. Genetics (2024)
Genomic technologies, such as targeted, exome and short-read genome sequencing approaches, have revolutionized the care of patients with rare genetic diseases. However, more than half of patients remain without a diagnosis. Emerging approaches from research-based settings such as long-read genome sequencing and optical genome mapping hold promise for improving the identification of disease-causal genetic variants. In addition, new omic technologies that measure the transcriptome, epigenome, proteome or metabolome are showing great potential for variant interpretation. As genetic testing options rapidly expand, the clinical community needs to be mindful of their individual strengths and limitations, as well as remaining challenges, to select the appropriate diagnostic test, correctly interpret results and drive innovation to address insufficiencies. If used effectively - through truly integrative multi-omics approaches and data sharing - the resulting large quantities of data from these established and emerging technologies will greatly improve the interpretative power of genetic and genomic diagnostics for rare diseases.
Keyphrases
- genome wide
- copy number
- dna methylation
- single cell
- end stage renal disease
- healthcare
- big data
- high resolution
- rna seq
- single molecule
- chronic kidney disease
- newly diagnosed
- mental health
- gene expression
- peritoneal dialysis
- palliative care
- prognostic factors
- patient reported outcomes
- chronic pain
- pain management
- high speed
- high density
- deep learning
- health insurance
- affordable care act